Workflow
北京阳光诺和药物研究股份有限公司 关于公司2025年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告

Core Viewpoint - The company has approved the 2025 Restricted Stock Incentive Plan and conducted a self-examination regarding insider trading among those privy to the plan's information, confirming compliance with regulations and no insider trading activities [1][6][4]. Group 1: Incentive Plan Approval - The company held its 19th meeting of the second board and the 4th meeting of the Compensation and Assessment Committee on May 12, 2025, where the 2025 Restricted Stock Incentive Plan was approved [1]. - The plan was developed in accordance with relevant laws and regulations, ensuring confidentiality and proper registration of insiders [1][6]. Group 2: Insider Trading Self-Examination - The company conducted a self-examination of insider trading activities among individuals privy to the incentive plan's information during the six months prior to its public disclosure [2]. - Two individuals were found to have traded the company's stock during the self-examination period, but their actions were based on publicly available information, and there was no evidence of insider trading [4][5]. - The company confirmed that all other insiders did not engage in any stock trading during the self-examination period, ensuring compliance with regulations [5][6]. Group 3: Shareholder Meeting - The company held its second extraordinary general meeting on May 28, 2025, where all proposed resolutions, including those related to the incentive plan, were approved without any objections [9][11]. - The meeting was conducted in accordance with legal and regulatory requirements, with all board members present [10][13].